Hutchmed China Limited Quick Ratio (HCM) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Hutchmed china Limited  (NASDAQ: HCM)

Hutchmed China Limited's Quick Ratio

HCM's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the fourth quarter 2025, Quick Ratio fell to 4.19 above Hutchmed China Limited average.

Within Major Pharmaceutical Preparations industry 219 other companies have achieved higher Quick Ratio than Hutchmed China Limited in fourth quarter 2025. While Quick Ratio total ranking has improved so far during the Q4 2025 to 928, from total ranking in the third quarter 2025 at 1085.

Explain Quick Ratio?
How much Cash & cash equivalents HCM´s has?
What are HCM´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

HCM Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change -16.49 % -16.14 % -18.95 % -16.14 % -6.7 %
Y / Y Cash & cash equivalent Change 63.44 % 63.53 % 69.96 % 63.53 % -5.66 %
Quick Ratio MRQ 4.19 4.33 4.23 4.33 2.14
HCM's Total Ranking # 928 # 1085 # # #
Seq. Current Liabilities Change 3.48 % -2.22 % 2.27 % -19.29 % 3.91 %
Seq. Cash & cash equivalent Change 0.07 % 0.12 % -0.12 % 63.32 % 0.13 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 220
Healthcare Sector # 362
Overall Market # 928


Quick Ratio Statistics
High Average Low
5.78 2.94 0.59
(Jun 30 2017)   (Dec 31 2015)




Financial Statements
Hutchmed China Limited's Current Liabilities $ 327 Millions Visit HCM's Balance sheet
Hutchmed China Limited's Cash & cash equivalent $ 1,368 Millions Visit HCM's Balance sheet
Source of HCM's Sales Visit HCM's Sales by Geography


Cumulative Hutchmed China Limited's Quick Ratio

HCM's Quick Ratio for the trailling 12 Months

HCM Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth -16.96 % -14.33 % -11.95 % -9.11 % -6.9 %
Y / Y Cash & cash equivalent TTM Growth 65.06 % 46.81 % 29.09 % 10.87 % -5.81 %
Quick Ratio TTM 4.27 3.67 3.13 2.59 2.15
Total Ranking TTM # 4487 # 3579 # # #
Seq. Current Liabilities TTM Growth -4.79 % -4.32 % -5.1 % -3.94 % -1.79 %
Seq. Cash & cash equivalent TTM Growth 10.76 % 12.05 % 14.62 % 16.03 % -1.49 %

Quick ratio ranking by company, industry and sector >> Back to HCM Financial Strength Comparisons >> Go to Compare HCM Quick Ratio to its Competitors

On the trailing twelve months basis HCM Cash & cash equivalent soared by 63.44 % in Q4 2025 year on year, while Current Liabilities rose to $327 millions, this led to increase in in Hutchmed China Limited's Quick Ratio to 4.27, above HCM average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 489 other companies have achieved higher Quick Ratio than Hutchmed China Limited. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 3579 to 4487.

Explain Quick Ratio?
How much Cash & cash equivalents HCM´s has?
What are HCM´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 490
Healthcare Sector # 987
Within the Market # 4487


trailing twelve months Quick Ratio Statistics
High Average Low
4.33 2.83 1.79
(Dec 31 2025)   (Dec 31 2022)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Major Pharmaceutical Preparations Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Mineralys Therapeutics Inc   11.44 $ 172.921  Millions$ 15.113  Millions
Avalyn Pharma Inc   11.33 $ 154.604  Millions$ 13.647  Millions
Innoviva Inc   11.09 $ 550.941  Millions$ 49.696  Millions
Bicycle Therapeutics Plc  11.02 $ 628.110  Millions$ 56.984  Millions
Ideaya Biosciences Inc   10.93 $ 639.388  Millions$ 58.476  Millions
Aardvark Therapeutics Inc   10.89 $ 110.027  Millions$ 10.107  Millions
First Tracks Biotherapeutics Inc   10.77 $ 311.638  Millions$ 28.943  Millions
Revium Rx.  10.29 $ 5.279  Millions$ 0.513  Millions
Sellas Life Sciences Group Inc   10.25 $ 71.893  Millions$ 7.017  Millions
Ovid Therapeutics Inc   10.16 $ 69.635  Millions$ 6.855  Millions
Praxis Precision Medicines Inc   10.05 $ 599.331  Millions$ 59.661  Millions
Whitehawk Therapeutics Inc   10.03 $ 145.697  Millions$ 14.519  Millions
Edesa Biotech Inc   10.01 $ 10.800  Millions$ 1.079  Millions
Neuphoria Therapeutics Inc   9.99 $ 14.311  Millions$ 1.433  Millions
Onkure Therapeutics Inc   9.97 $ 59.050  Millions$ 5.921  Millions
Immix Biopharma Inc   9.93 $ 100.409  Millions$ 10.111  Millions
Pmv Pharmaceuticals Inc   9.89 $ 112.943  Millions$ 11.415  Millions
Galera Therapeutics Inc   9.88 $ 6.375  Millions$ 0.645  Millions
Olema Pharmaceuticals Inc   9.76 $ 505.437  Millions$ 51.802  Millions
Erasca Inc   9.68 $ 276.075  Millions$ 28.511  Millions
Bioage Labs Inc   9.58 $ 192.920  Millions$ 20.138  Millions
Relmada Therapeutics Inc  9.57 $ 93.006  Millions$ 9.723  Millions
Ataibeckley Inc   9.40 $ 220.651  Millions$ 23.479  Millions
Viking Therapeutics Inc   9.22 $ 705.739  Millions$ 76.530  Millions
Unicycive Therapeutics Inc  9.02 $ 41.269  Millions$ 4.574  Millions
Lisata Therapeutics Inc   8.99 $ 27.596  Millions$ 3.071  Millions
Calcimedica Inc   8.97 $ 13.016  Millions$ 1.451  Millions
Capricor Therapeutics inc   8.88 $ 318.129  Millions$ 35.837  Millions
Moonlake Immunotherapeutics  8.66 $ 393.968  Millions$ 45.478  Millions
Boundless Bio Inc   8.58 $ 107.581  Millions$ 12.537  Millions

Date modified: 2026-07-07T11:20:53+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.